Hims' Partner to Reintroduce Controversial GLP-1 Pill After Regulatory Halt
Summary
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded GLP-1 weight-loss pill, which was previously pulled from the market due to U.S. regulatory pushback. This development follows Hims' earlier announcement of offering a low-cost compounded semaglutide, a move that drew significant criticism from Novo Nordisk and an FDA referral to the Department of Justice. While the reintroduction signals Hims' intent to continue pursuing the lucrative weight-loss market, Strive Pharmacy has not yet set a firm timeline, indicating ongoing caution. This is a material update for Hims' product strategy and competitive positioning, but the persistent regulatory risks, including the DOJ referral, remain a significant overhang.
At the time of this announcement, HIMS was trading at $15.53 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.